Skip to main content

Market Overview

Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients

Share:
Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients
  • Aprea Therapeutics Inc (NASDAQ: APREhas announced that the Phase 1/2 trial evaluating eprenetapopt in acute myeloid leukemia (AML) has met the pre-specified primary efficacy endpoint of complete remission (CR) rate.
  • The trial is assessing eprenetapopt with venetoclax and azacitidine in patients with TP53 mutant AML.
  • In 30 patients who were evaluable for efficacy at the time of the analysis, the CR rate was 37%.
  • The composite rate of CR plus CR with incomplete hematologic recovery (CRi), CR/CRi, was 53%.
  • Eleven patients remain on study treatment and continue to be followed for safety and efficacy as of the data cut.
  • The Company plans to discuss the dataset with the FDA in the second half of 2021.
  • Data from the trial will be presented at a future scientific or medical conference.
  • Price Action: APRE shares are up 49.7% at $7.26 during the premarket session on the last check Wednesday.
 

Related Articles (APRE)

View Comments and Join the Discussion!

Posted-In: Briefs leukemiaBiotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com